class="entry-header"

Monon Bioventures awarded nearly $400,000 from the National Cancer Institute

December 7, 2023September 22, 2022 by Elaine Bammerlin

Monon Bioventures will be partnering with fellow ICBI company, Genezen, and the Purdue University College of Pharmacy to study the feasibility of manufacturing a glioblastoma therapeutic using human immune natural killer (NK) cells, a therapeutic created at the Purdue University College of Pharmacy.